Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MAX-4 by MaxiNovel Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval
MAX-4 is under clinical development by MaxiNovel Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
MAX-4 by MaxiNovel Pharmaceuticals for Solid Tumor: Likelihood of Approval
MAX-4 is under clinical development by MaxiNovel Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
MAX-4 by MaxiNovel Pharmaceuticals for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
MAX-4 is under clinical development by MaxiNovel Pharmaceuticals and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
MAX-4 by MaxiNovel Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
MAX-4 is under clinical development by MaxiNovel Pharmaceuticals and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
MAX-4 by MaxiNovel Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval
MAX-4 is under clinical development by MaxiNovel Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...